Product Description
Mechanisms of Action: RNA polymerase Inhibitor, RNA Synthesis Inhibitor, Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Greece | Ireland | New Zealand | South Africa
Approved Indications: None
Known Adverse Events: None
Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Gastrointestinal Cancer|Mesothelioma|Esophageal Cancer|Breast Cancer|Digestive System Cancer|Lung Cancer|Sarcoma, Ewing|Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02859415 |
16-C-0152 | P2 |
Terminated |
Mesothelioma|Sarcoma|Esophageal Cancer |
2019-12-06 |
2022-04-06 |
Primary Endpoints|Treatments |
|
NCT01624090 |
12-C-0151 | P2 |
Terminated |
Esophageal Cancer|Breast Cancer|Lung Cancer|Digestive System Cancer|Gastrointestinal Cancer|Mesothelioma |
2019-08-20 |
2020-01-02 |
||
NCT01610570 |
12-C-0135 | P2 |
Terminated |
Sarcoma, Ewing |
2014-05-21 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|